Stay updated on SNDX-5613 Combo with Chemo in Relapsed Leukemia Clinical Trial

Sign up to get notified when there's something new on the SNDX-5613 Combo with Chemo in Relapsed Leukemia Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the SNDX-5613 Combo with Chemo in Relapsed Leukemia Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.0%
    Check dated 2024-06-13T22:39:22.000Z thumbnail image
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    8 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating an update in the phase II trial testing the safety and best dose of SNDX-5613 in combination with chemotherapy for infants and young children with relapsed or refractory KMT2A-R leukemia.
    Difference
    0.0%
    Check dated 2024-06-06T14:40:43.000Z thumbnail image
  7. Check
    23 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to provide detailed eligibility criteria for study participants, including age, initial diagnosis, and specific genetic markers. Previously, this section had no information provided.
    Difference
    40%
    Check dated 2024-05-22T21:24:14.000Z thumbnail image
  8. Check
    45 days ago
    Change Detected
    Difference
    0.4%
    Check dated 2024-04-30T22:52:28.000Z thumbnail image

Stay in the know with updates to SNDX-5613 Combo with Chemo in Relapsed Leukemia Clinical Trial

Enter your email address, and we'll notify you when there's something new on the SNDX-5613 Combo with Chemo in Relapsed Leukemia Clinical Trial page.